Nikki Lee

Dr. Nikki Lee

Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2018 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
NLNikki Lee
Nikki Lee
CCChung Man Chan
Chung Man Chan
LTLai Nar Tung
Lai Nar Tung
HWHector K. Wang
Hector K. Wang
SLSimon Law
Simon Law
Esophageal squamous cell carcinoma (ESCC) is the predominant subtype of esophageal cancer worldwide and highly prevalent in less developed regions. Management of ESCC is challenging and involves multimodal treatments. Patient prognosis is generally poor especially for those diagnosed in advanced disease stage. One factor contributing to this clinical dismal is the incomplete understanding of disease mechanism, for which this situation is further compounded by the presence of other limiting factors for disease diagnosis, patient prognosis and treatments. Tumor xenograft animal models including subcutaneous tumor xenograft model, orthotopic tumor xenograft model and patient-derived tumor xenograft model are vital tools for ESCC research. Establishment of tumor xenograft models involves the implantation of human ESCC cells/xenografts/tissues into immunodeficient animals, in which mice are most commonly used. Different tumor xenograft models have their own advantages and limitations, and these features serve as key factors to determine the use of these models at different stages of research. Apart from their routine use on basic research to understand disease mechanism of ESCC, tumor xenograft models are actively employed for undertaking preclinical drug screening project and biomedical imaging research.

8 December 2009 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
NLNikki Lee
Nikki Lee
FTFelice H. Tsang
Felice H. Tsang
FSFelix H. Shek
Felix H. Shek
MMMao Mao
Mao Mao
HDHongyue Dai
Hongyue Dai
JLJohn M. Luk
John M. Luk
Using comparative proteomic and genomic approaches, the authors identified eukaryotic translation initiation factor 5A (eIF5A) as an oncofetal molecule highly abundant in mouse embryonic livers and human hepatocellular carcinoma (HCC) cell lines. To evaluate the oncogenic role and prognostic significance of eIF5A in HCC, we investigate the expression patterns of the two isoforms (eIF5A1 and eIF5A2) in a cohort of 258 HCC cases by cDNA microarray. Both eIF5A isoforms were expressed in the tumors, and clinically correlated eIF5A1 with more numbers of tumor nodules and eIF5A2 with tumor venous infiltration in HCC. In a separate cohort of 50 HCCs, high level of eIF5A2, but not eIF5A1, was associated with elevated levels of deoxyhypusine synthase and deoxyhypusine hydroxylase that catalyze post‐translational hypusination of eIF5A protein. Interestingly, N1‐guanyl‐1,7‐diaminoheptane (GC7), which is an inhibitor for the first step of eIF5A hypusination, was shown to significantly impair the cell proliferation and invasion of primary HCC cells (HepG2 and Hep3B). To further demonstrate the tumorigenic role associated with eIF5A, a drastic reduction of cell proliferation was associated with suppression of eIF5A2 by transfecting Hep3B, H2‐P and H2‐M HCC cells expressing high level of this isoform using small interfering RNA (siRNA) against eIF5A2. For these assays, a milder response was usually observed in normal hepatocyte cell line. Therefore, these findings suggest that eIF5A plays an important role in HCC tumorigenesis and metastasis, and targeting eIF5A hypusination by GC7 inhibitor or eIF5A2 by RNA interference (RNAi) may offer new therapeutic alternatives to HCC patients.

9 May 2014 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
FTFelice H. Tsang
Felice H. Tsang
VAVictor Au
Victor Au
WLWen-Jing Lu
Wen-Jing Lu
FSFelix H. Shek
Felix H. Shek
ALAngela M. Liu
Angela M. Liu
NLNikki Lee
Nikki Lee

1 February 2015 in Genomics
Verified
Journal Article
Closed access
LKLin Kang
Lin Kang
XLXiaoqiao Liu
Xiaoqiao Liu
ZGZhoulin Gong
Zhoulin Gong
HZHancheng Zheng
Hancheng Zheng
JWJun Wang
Jun Wang
RCRonghua Chen
Ronghua Chen

1 January 2015 in Cancer Growth and Metastasis
Verified
Journal Article
Open access
Nelson YeeNelson Yee
Nelson Yee
NINatalia A. Ignatenko
Natalia A. Ignatenko
NFNiklas Finnberg
Niklas Finnberg
NLNikki Lee
Nikki Lee
DSDouglas Stairs
Douglas Stairs
Introductory Editorialpublished_or_final_versio

18 September 2012 in International Journal of Hepatology
Verified
Journal Article
Open access
PDF file
FSFelix H. Shek
Felix H. Shek
SFSarwat Fatima
Sarwat Fatima
NLNikki Lee
Nikki Lee
Hepatocellular carcinoma (HCC) is a primary liver malignancy and accounts for most of the total liver cancer cases. Lack of treatment options and late diagnosis contribute to high mortality rate of HCC. In eukaryotes, translation of messenger RNA (mRNA) to protein is a key process in protein biosynthesis in which initiation of translation involves interaction of different eukaryotic translation initiation factors (eIFs), ribosome subunits and mRNAs. Eukaryotic translation initiation factor 5A (eIF5A) is one of the eIFs involved in translation initiation and eIF5A2, one of its isoforms, is upregulated in various cancers including HCC as a result of chromosomal instability, where it resides. In HCC, eIF5A2 expression is associated with adverse prognosis such as presence of tumor metastasis and venous infiltration. Based on eIF5A2 functional studies, suppressing eIF5A2 expression by short interfering RNA alleviates the tumorigenic properties of HCC cellsin vitrowhile ectopic expression of eIF5A2 enhances the aggressiveness of HCC cellsin vivoandin vitroby inducing epithelial-mesenchymal transition. In conclusion, eIF5A2 is a potential prognostic marker as well as a therapeutic target for HCC.